NewLink Genetics (NASDAQ:NLNK) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.
A number of other equities research analysts have also recently commented on NLNK. Zacks Investment Research cut NewLink Genetics from a “buy” rating to a “hold” rating in a research note on Thursday. ValuEngine cut NewLink Genetics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Jefferies Group upgraded NewLink Genetics from a “hold” rating to a “buy” rating and lifted their target price for the stock from $7.00 to $26.00 in a research note on Friday, September 8th. Cantor Fitzgerald reiterated a “buy” rating and set a $26.00 target price on shares of NewLink Genetics in a research note on Monday, September 25th. Finally, Stifel Nicolaus lifted their target price on NewLink Genetics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $23.29.
NewLink Genetics (NASDAQ:NLNK) traded down $1.06 during midday trading on Friday, hitting $9.00. The stock had a trading volume of 1,843,328 shares, compared to its average volume of 731,002. NewLink Genetics has a 12 month low of $5.90 and a 12 month high of $25.17.
ILLEGAL ACTIVITY WARNING: “BidaskClub Upgrades NewLink Genetics (NLNK) to “Hold”” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.com-unik.info/2018/01/07/bidaskclub-upgrades-newlink-genetics-nlnk-to-hold.html.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.